Analysis Population
All Participants Randomized

	Placebo n (%)	Xanomeline Low Dose n (%)	Xanomeline High Dose n (%)
Participants in population	86	84	84
Participants included in ITT population	86 (100.0)	84 (100.0)	84 (100.0)
Participants included in efficacy population	79 (91.9)	81 (96.4)	74 (88.1)
Participants included in safety population	86 (100.0)	84 (100.0)	84 (100.0)

Source: ADSL dataset